Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

被引：0
|
作者：
Montgomery, Robert B.
Eisenberger, Mario A.
Rettig, Matthew
Chu, Franklin
Pili, Roberto
Stephenson, Joe
Vogelzang, Nicholas J.
Morrison, Jodie
Taplin, Mary-Ellen
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Johns Hopkins Univ, James Buchanan Brady Urol Inst, Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] San Bernadino Urol Associates, San Bernardino, CA USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[6] Canc Ctr Carolinas, Greenville, SC USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] US Oncol Res, Las Vegas, NV USA
[9] Tokai Pharmaceut, Boston, MA USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4665
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
    Wang, Jue
    McGuire, Timothy R.
    Schwarz, James K.
    Meza, Jane L.
    Talmadge, James E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [32] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Zhang, Hongyong
    Wang, Yu
    Ghosh, Paramita
    Lara, Primo N., Jr.
    Pasquinelli, Patricia
    Beckett, Laurel
    White, Ralph W. deVere
    Pan, Chong-Xian
    CANCER RESEARCH, 2010, 70
  • [33] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Pan, C.
    Ghosh, P.
    Suga, J. M.
    Paequinelli, P.
    Beckett, L.
    White, R. Deere
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Attard, Gerhardt
    Reid, Alison H. M.
    A'Hern, Roger
    Parker, Christopher
    Oommen, Nikhil Babu
    Folkerd, Elizabeth
    Messiou, Christina
    Molife, L. Rhoda
    Maier, Gal
    Thompson, Emilda
    Olmos, David
    Sinha, Rajesh
    Lee, Gloria
    Dowsett, Mitch
    Kaye, Stan B.
    Dearnaley, David
    Kheoh, Thian
    Molina, Arturo
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
  • [35] The effect of novel CYP17 inhibitor galeterone on gonadal and tumor progestogen and androgen levels in SLID mice bearing LNCaP prostate cancer xenografts
    Schech, Amanda J.
    Sabnis, Gauri J.
    Yu, Stephen
    Njar, Vincent C. O.
    Jacoby, Douglas B.
    Nelson, Peter
    Dumpit, Ruth
    Brodie, Angela M. H.
    CANCER RESEARCH, 2016, 76
  • [36] Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): Results from a phase I-II clinical trial
    Garcia, Jorge A.
    Elson, Paul
    Tyler, Allison
    Triozzi, Pierre
    Dreicer, Robert
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 33.e11 - 33.e17
  • [37] A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
    Pan, Chong-xian
    Lara, Primo
    Evans, Christopher P.
    Parikh, Mamta
    White, Ralph de Vere
    Dall'era, Marc
    Liu, Chengfei
    Robles, Daniel
    Gao, Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [38] A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).
    Mckay, Rana R.
    Werner, Lillian
    Jones, Alexandra
    Choudhury, Atish Dipankar
    Pomerantz, Mark
    Sweeney, Christopher
    Bubley, Glenn J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven
    Attard, Gerhardt
    Reid, Alison H. M.
    Olmos, David
    de Bono, Johann S.
    CANCER RESEARCH, 2009, 69 (12) : 4937 - 4940
  • [40] Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy-naive and docetaxel treated castration-resistant prostate cancer (CRPC)
    Attard, G.
    Reid, A.
    Oommen, N. Babu
    Folkerd, L.
    Olmos, D.
    Thompson, E.
    Maier, G.
    Dowsett, M.
    Dearnaley, D.
    De Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 51 - 51
12345